Forward Science: The next chapter in pancreatic cancer research

Pankind Scientific Meeting 2026

Friday 30 October 2026, Swissotel, Sydney

Questions for speakers

Have a question for our speakers? Send it through Slido during each session and we’ll put it to them in the Q&A.

OPEN SLIDO

Michelle Stewart

Michelle Stewart
Chief Executive Officer

Welcome from our CEO

Dear Guests,

On behalf of Pankind, Pancreatic Cancer Australia, it is my great pleasure to welcome you to our 2026 Scientific Meeting.

Last year's meeting, The Road to Treatment' showed a field at a turning point, with emerging KRAS inhibitors, precision diagnostics and the promise of earlier detection. This year's theme, Forward Science: The next chapter in pancreatic cancer research', asks where we go from here. The choices we make now, about which questions to pursue and how to carry discovery into care, will shape outcomes for years to come.

Read more

Those choices are best made together. Progress rarely comes from one lab working alone. It comes from a scientist hearing what a surgeon sees in theatre, or a collaboration that starts over coffee. Many ideas for the next chapter will begin here.

This year Pankind will make its highest ever investment in research. We seed fund bold, early-stage ideas so they can build the proof of concept to attract larger investment. We are also working to remove the barriers that slow research, focusing on bioresources, centres of excellence and surgical volume.

Our resource Living with Pancreatic Cancer is now joined by "When Surgery Is Not an Option". Our Support Navigation Program is growing, particularly in clinical trial navigation and risk pathways, and our new Carer Support Program offers structured counselling initially designed by Vanessa Beesley and Rachel Neale at QIMR Berghofer.

Understanding risk remains a priority. We support surveillance for people with a family history at the Jreissati Pancreatic Centre at Epworth Hospital and are building access to familial genomic testing. We also advocate for timely access to genomic profiling, clinical trials and new treatments. Discovery only changes lives when it reaches people.

We are especially proud that our Head of Research, Amber Johns, has been a critical part of the Lancet Oncology Commission on Accelerating Equitable Cancer Genomics and Precision Oncology, a landmark global initiative working to make genomics and precision oncology accessible to everyone with cancer.

Our mission is bold: to triple pancreatic cancer survival by 2030. We will not get there alone, and we do not have to.

During this meeting, I encourage you to ask the hard questions, share the unfinished idea and leave with at least one new connection. That is how the next chapter gets written.

Thank you for your passion, persistence and partnership. Your work gives hope to every person and family affected by pancreatic cancer.

With best wishes,
Michelle Stewart
Chief Executive Officer

2026 Program

8:30 - 8.50

Arrival and poster set up

9:00

Welcome and introductions
Michelle Stewart, CEO

9:10–10:30

Plenary Session

Chair: Amber Johns

Dr Wungki Park
GI Medical Oncologist, Memorial Sloan Kettering Cancer Center, USA
Pancreatic Cancer: From Biology to Breakthroughs

Prof David Chang
Chair of Surgical Oncology, University of Glasgow, UK
Pancreatic Cancer: From Pixel to Patient

10:30–11:10

Morning tea and posters

11:10–12:10

Session 1: New Treatments and Targeted Therapies

Chair: Chris Baggoley

Dr Mark Adams, QUT
Restoring Chemotherapy Sensitivity by Targeting a Novel Driver of Resistance in Pancreatic Cancer

Prof John Hooper, University of Queensland
Illuminating and Eliminating - Payloaded Antibodies for Pancreatic Cancer Detection and Therapy

12:10–12:55

Session 2: Panel Discussion

Accelerating the Pipeline: What Will It Take to Move Faster?

Moderator: Steve Robson

12:55–14:25

Lunch break / Poster walkaround

14:25–15:25

Session 3: Early Detection

Dr Chamini Perera, UNSW
Deciphering the Exosomal RNA Cargo Involved in Pancreatic Cancer-Related Diabetes

Dr Michaela Kindlova, University of Queensland
Beyond the sequence: Elucidation of epigenetic drift in pancreatic cancer

Prof Andrew Metz, Epworth HealthCare
Pancreatic cancer surveillance and the APRISE program

15:25–16:00

Session 4: Moderated Group Discussion

Moderator: Amber Johns

This session picks up where the day’s talks leave off. We’ll ask you for
the one priority, or big-ticket item, you’d back to move pancreatic cancer
research forward in Australia. We’ll also return to questions from the
panel and earlier sessions that ran out of time. The aim is a practical
answer to one question: how can we work better together?

16:00–16:20

Afternoon tea

16:20–16:35

Award Presentations

Chair: Ross McKinnon

Poster Prize
Most outstanding presentation, as judged by the Scientific Committee

Pankind Research Impact Award
Scientific excellence and the real-world difference that research can make to patients and their families

16:35–16:45

Closing Remarks

17:00–19:00

Networking Drinks
Ten Stories Upper Deck Bar (Level 8)

Plenary session speakers

We're thrilled to welcome two global leaders to our plenary session: Dr. Wungki Park from Memorial Sloan Kettering Cancer Center, New York, and Professor David Chang, the Chair of Surgical Oncology at the University of Glasgow. 

Wungki Park Headshot

Dr Wungki Park

Dr Wungki Park is a GI medical oncologist and physician-scientist at Memorial Sloan Kettering Cancer Center specialising in pancreatic and biliary cancers, with a research program focused on first-in-human novel KRAS-directed therapies, DNA damage repair biology, and immune modulation.

Read more

He leads multiple investigator-initiated and industry clinical trials. His lab (sPARK lab) integrates genomics, single-cell, spatial and computational data analysis to define tumor evolution, cachexia mechanisms, and therapeutic vulnerabilities, and uses AI-technologies for early detection and pathology biomarkers for treatments in pancreatic cancer.

He is a founder of GRIT (GI RAS Innovative Therapeutics), and this initiative focuses on translational science and developmental therapeutics for RAS-driven GI cancers. He is deeply committed to mentoring the next generation of physician–scientists and advancing innovative, patient-centered approaches to improve outcomes in these historically lethal cancers.

David Chang Headshot

Professor David Chang

Professor David Chang holds the Chair of Surgical Oncology at the University of Glasgow. His research focuses on a better understanding of the molecular pathology of pancreatic cancer to inform novel therapeutic strategies.

Read more

Professor Chang undertook his HPB and Upper GI Surgery fellowship, PhD, and post-doctoral training in Australia. He was recruited to the University of Glasgow in 2013 as part of the research initiative for precision medicine in Scotland.

He leads Precision-Panc, a UK national therapeutic development platform to deliver personalised cancer care for pancreatic cancer. Professor Chang is also the UK lead of the European Horizon H2020-funded pancreatic cancer AI consortium, PANCAIM, which aims to develop AI and machine learning applications to better understand pancreatic cancer molecular pathology and treatment for patients. He also took up the Chair of the UK National Pancreatic Cancer Research Group in 2025, driving the national pancreatic cancer clinical research priorities.

Session speakers

Mark Adams Headshot

Dr Mark Adams

Senior Research Fellow at the Queensland University of Technology

Marina Pajic

Marina Pajic

University of Sydney

Professor John Hooper

Professor John Hooper

Mater Research Institute, The University of Queensland

Dr Chamini Perera

Dr Chamini Perera

UNSW Sydney

Dr Michaela Kindlova

Dr Michaela Kindlova

Mater Research, Translational Bioinformatics Group

Prof Andrew Metz

Professor Andrew Metz

Jreissati Pancreatic Centre at Epworth

Panel discussion

Accelerating the Pipeline: What Will It Take to Move Faster?

New targets and a wave of RAS-targeted therapies are changing what is possible in pancreatic cancer. Our panel asks what it will take to move faster. Join the conversation on the barriers that slow progress, and the practical changes that could shorten the path from discovery to the clinic.

Steve Robson

Steve Robson

Panel discussion chair

Clinician and surgeon, author and leader in health policy

Poster abstracts

We encourage you to explore the research posters on display and discover more of the exciting work being undertaken across the pancreatic cancer research community.

A large molecular model of cancer harmonizes bioprinted PDAC co-cultures with patient biology
Principal Investigator: Joe Gillson
Institution: Inventia Life Science

68Ga-FAPI-46 PET/CT Versus 18F-FDG PET/CT for Pancreatic Cancer: A Feasibility Study
Principal Investigator: Yvette Coulon
Institution: I-Med Radiology

Enhancing the efficacy of and overcoming resistance to Kras Inhibitors in Pancreatic Cancer
Principal Investigator: Niahm Mills
Institution: Garvan

Pinpointing and targeting novel drivers of pancreatic cancer progression and metastasis using TRAP-seq
Principal Investigator: Michael Trpceski
Institution: Garvan

Development of an immune-humanised mouse model for pancreatic cancer research
Principal Investigator: Diana Schumacher
Institution: Garvan

High-throughput plasma affinity proteomic profiling identifies a candidate biomarker to improve early-stage pancreatic ductal adenocarcinoma detection
Principal Investigator: Stellene Vitaro
Institution: Flinders

Therapeutic potential of co-targeting PRMT5 and MAT2A in MTAP-loss pancreatic cancer
Principal Investigator: Johana Luhur
Institution: Garvan

Targeting the NPY/NPY1R signaling axis in mutant p53–dependent pancreatic cancer impairs metastasis
Principal Investigator: David Herrmann
Institution: Garvan

The Australian Pancreatic High-RIsk ScrEening (APRISE) Program
Principal Investigator: Halina Pietrzak
Institution: Jreissati Centre, Epworth

Primary cancer associated fibroblasts alter PDAC tumour organoid subtype through epigenetic regulation
Principal Investigator: Emilie Jaune
Institution: Frazer Institute, University of Queensland

Co-targeting thrombospondin-1 (THBS-1) to improve KRAS inhibitor efficacy in pancreatic cancer
Principal Investigator: Victoria Tyma
Institution: Garvan

Targeting Pain Pathways in Pancreatic Cancer: Validation of CXCL12-CXCR4 Axis
Principal Investigator: Joseph Cheung
Institution: Ingham Institute

Defining and Evaluating Lithium as a Modulator of the Tumour Immune Microenvironment in difficult to treat tumours
Principal Investigator: Jessica Jenner
Institution: Garvan Institute

Hunting Hidden Tumours: Nanobots for wireless detection of Pancreatic Cancer
Principal Investigator: William Louis
Institution: RMIT

The Effect of Nutrient Availability and KRAS Mutations on Daraxonrasib Treatment in PDAC Cell Lines
Principal Investigator: Justin Moon
Institution: Victor Chang

Large-scale pharmacotranscriptomics maps genotype- and cell-state-specific drug responses in pancreatic cancer
Principal Investigator: Daksh Pamar
Institution: Melbourne University

PemOla: A phase II study combining pembrolizumab with olaparib in metastatic pancreatic adenocarcinoma patients with mismatch repair deficiency or tumour mutation burden ≥ 4 mutations/Mb
Principal Investigator: Sandra Hayes
Institution: GI Cancer Trials

Stromal precision targeting sensitizes mouse pancreatic cancer to immune checkpoint inhibition
Principal Investigator: Bo He
Institution: Harry Perkins Institute of Medical Research

Nanomotors for the early detection of Pancreatic Ductal Adenocarcinoma
Principal Investigator: Srikrishnan Ramachandran
Institution: Deakin University

Research grant recipients

Early Detection Innovation

Funds innovation research to improve early detection and diagnosis of pancreatic cancer by supporting feasibility and proof-of-concept studies.

Improving early detection of pancreatic cancer by exploring the faulty methylation of pre-cancerous tissue
Principal Investigator: Michaela Kindlova

Seeing the unseen: a targeted fluorescent probe to detect otherwise invisible pre-cancerous lesions in the pancreas
Principal Investigator: William McGahan

Simultaneous targeted methylome and genome sequencing from early-stage pancreatic cancer as a sensitive, multi-factor liquid biopsy
Principal Investigator: Orion Tong

Pancreatic Cancer-Related Diabetes: A Critical Juncture for Pancreatic Cancer Detection
Principal Investigator: Chamini Perera

Metabolism-Driven Biomarker Discovery for Early Detection of PDAC
Principal Investigator: Nils Halberg

New Treatment Innovation 

Supports early-stage research to develop new treatments, diagnostics, or quality-of-care improvements for pancreatic cancer.

Starving the Enemy: Undermining CAF-Driven Metabolic Support in PDAC to Reawaken Immune Defence
Principal Investigator: Zaklina Kovacevic

Exploiting Shared Cancer Antigens for Off-the-Shelf Immunotherapy in Pancreatic Cancer
Principal Investigator: Pouya Faridi

Unlocking Synergy: Drug Combinations Targeting Critical Survival Factors for Enhanced Therapeutic Efficacy in Pancreatic Cancer
Principal Investigator: Walter Fairlie

Targeting lipid desaturase activity to enhance chemotherapy response in pancreatic cancer
Principal Investigator: Sarah Hancock

Augmenting a novel mechanism to restore pancreatic cancer response to treatment
Principal Investigator: Mark Adams

New Treatment Accelerator 

Funds advanced research to fast-track new treatments from the lab to clinical application, driving real-world impact.

Developing the Next-Generation T Cell Therapy for Pancreatic Cancer via Precision Genome Editing
Principal Investigator: Isabelle Munoz

Selective inhibition of integrin signalling as a novel precision medicine approach: targeting treatment resistance in pancreatic cancer
Principal Investigator: Marina Pajic

Novel antibody-based drugs to target pancreatic tumours
Principal Investigator: Peter Janes

Panc-PET - a molecular-imaging trial to guide targeted therapy for pancreatic cancer
Principal Investigator: John Hooper

DISCOVERY-P: Adaptive study evaluating new therapies in early-stage pancreatic cancer utilising circulating tumour DNA (ctDNA) to guide adjuvant therapy selection
Principal Investigator: Belinda Lee

2024 Early Detection Innovation Grants

Development of a non-invasive urine screening test to identify patients with early pancreatic cancer (Marianne Allan Pancreatic Cancer Research Grant)
Principal Investigator: Belinda Lee
Institute: Walter and Eliza Hall Institute of Medical Research

Single extracellular vesicle analysis to identify high-risk pancreatic cancer precursor lesions
Principal Investigator: Ying Zhu
Institute: University of Technology Sydney

Exploring the plasma proteome to find biomarkers that can detect early-stage pancreatic ductal adenocarcinoma
Principal Investigator: Jean Winter
Institute: Flinders University

2024  New Treatment Grants

Enhancing the efficacy of and overcoming resistance to Kras Inhibitors in Pancreatic Cancer
Principal Investigator: Kendelle Murphy
Institute: Garvan Institute of Medical Research 

Targeting fibrosis to improve clinical KRAS G12D inhibitor MRTX1133 efficacy in pancreatic cancer
Principal Investigator: Brooke Pereira
Institute: Garvan Institute of Medical Research

Novel radiopharmaceutical therapies targeting tumour stroma for treating pancreatic cancer
Principal Investigator: Andrew Scott
Institute: Olivia Newton-John Cancer Research Institute

Advancing a new targeted antibody to combat pancreatic cancer
Principal Investigator: Claudine Bonder
Institute: University of South Australia

2023 Early Detection Innovation Grant (Marianne Allan Pancreatic Cancer Research Grant)

Development of a blood based test to identify patients with early pancreatic cancer.
Principal Investigator: Dr Belinda Lee
Institute: Walter and Eliza Hall Institute of Medical Research

2023 New Treatment Grants

Receptor-directed precision medicines for pancreatic cancer
Principal Investigator: Prof John Hooper
Institute: Royal Brisbane and Women's Hospital

PemOla: A phase II study combining pembrolizumab and olaparib in metastatic pancreatic adenocarcinoma patients with high tumour mutation burden
Principal Investigator: Dr Daniel Croagh
Institute: Australian Gastro Intestinal Trials Group

Targeting oncogenic Pol-II transcription cycles using cyclin-dependent-kinase inhibitors: a new therapeutic approach for pancreatic cancer
Principal Investigator: Prof Ricky Johnstone
Institute: University of Melbourne

 

Targeting lymph-pancreas interactions to treat pancreatic cancer
Principal Investigator: Dr Enyuan Cao
Institute: Monash University

 

New pancreatic cancer treatment involving Aryl Hydrocarbon Receptor (AhR) inhibition in the tumour and microenvironment
Principal Investigator: A/Prof Jennette Sakoff
Institute: Calvary Mater Newcastle

 

Polymer mimics of the TRAIL protein for pancreatic cancer
Principal Investigator: Dr Robert Chapman
Institute: The University of Newcastle

2022 Early Detection Innovation Grants

Lighting up the needle in the haystack: targeting malignant stroma to detect early pancreatic cancer on PET.
Principal Investigator: A/Prof David Cavallucci
Institute: Royal Brisbane and Women's Hospital

Development of an early detection biomarker for pancreatic cancer.
Principal Investigator: A/Prof Jason Lee
Institute: QIMR Berghofer Medical Research Institute

A blood test for early detection of pancreatic cancer by single extracellular vesicle analysis.
Principal Investigator: Dr Ying Zhu
Institute: University of Technology Sydney

Identifying metabolic changes in pancreatic fibroblasts during development of pancreatic cancer to facilitate early detection.
Principal Investigator: Dr Zaklina Kovacevic
Institute: The University of Sydney

2022 New Treatment Accelerator Grants

Trapping pancreatic cancer in a crossfire: investigating a combination treatment approach designed to eradicate pancreatic cancer.
Principal Investigator: Dr Alex Staudacher and Dr Vasilios Liapis
Institute: Central Adelaide Local Health Network

Targeting epigenetic modifying enzymes as a novel therapy for pancreatic cancer.
Principal Investigator: A/Prof Jason Lee
Institute: QIMR Berghofer Medical Research Institute

Advanced analysis of lipid metabolism in pancreatic cancer to reveal new therapeutic targets
Principal Investigator: Prof Nigel Turner
Institute: Victor Chang Cardiac Research Institute

Using precision medicine approaches in pancreatic cancer to improve chemosensitivity via porcupine inhibition.
Principal Investigator: Dr Sean Porazinski
Institute: Garvan Institute of Medical Research

2021 Early Detection Innovation Grants

1Development of Biomarker Tests for Early Detection/Diagnosis of Pancreatic Cancer.
Principal Investigator: Prof Anubhav Mittal
Institute: The University of Sydney

Advancing a novel ‘early detection’ biomarker for PDAC.
Principal Investigator: Prof Claudine Bonder
Institute: Centre for Cancer Biology

Deciphering the Exosomal RNA Cargo in Pancreatic Cancer-related diabetes using Transcriptmonics: A Novel Approach for Early Detection of Pancreatic Cancer
Principal Investigator: Dr Chamini Perera
Institute: The University of New South Wales

Early Detection and Diagnosis of Pancreatic Cancer using Circulating Tumour Cells.
Principal Investigator: Prof John Rasko
Institute: The University of Sydney

Can the molecules carried by exosomes help to diagnose pancreatic cancer early?
Principal Investigator: Prof Marco Falasca
Institute: Curtin University

2021 New Treatment Accelerator Grants

3D Human Tumour Explant Culture to Inform Precision Medicine in Pancreatic Cancer.
Principal Investigator: Dr George Sharbeen
Institute: The University of New South Wales

Spatial Transcriptomics a Pathway to Dissecting Barriers to Effective Treatment in Pancreatic Cancer.
Principal Investigator: Prof Phoebe Phillips
Institute: The University of New South Wales

Repurposing FDA/TGA-approved PCSK9 inhibitor evolocumab to enhance immunotherapy outcomes in pancreatic cancer.
Principal Investigator: Prof Paul Timpson and Dr Brooke Pereira
Institute: Garvan Institute of Medical Research

Pankind offers a range of competitive and strategic funding opportunities throughout the year, ensuring researchers have access to the resources needed to accelerate scientific advancements.

Every week matters. Campaign tile featuring Dee, Judi, David, Gianna, Leigh and Mona.

Every week matters

For people living with pancreatic cancer, time is precious. Through our Every Week Matters campaign, we’re advocating for faster, more flexible pathways to access new medicines, so promising treatments can reach people sooner.

Add your voice and help us make the case for change.

ADD YOUR VOICE

Pankind patient and carer resources

Pankind supports people impacted by pancreatic cancer by providing relevant information, valuable resources and a connection to others affected by the disease.

We encourage you to share our resource pages with any patient, carer or community members you connect with. Our resources are provided free of charge on both soft and hard copies. You can also email info@pankind.org.au for any additional patient or support related enquiries.

Thank you to our sponsors

Pankind, Pancreatic Cancer Australia, respectfully acknowledges the Gadigal people of the Eora nation as the Traditional Custodians of this land on which we meet today. We would also like to pay our respects to Elders past, present and emerging.